News Related to Pulmonary Hypertension

Related coverage linked through entity extraction aliases.

Compass Therapeutics Reports Mixed Biliary Tract Cancer Data, Plans FDA Meeting for Tovecimig BLA

Apr 28, 2026

Compass Therapeutics reported mixed Phase 2/3 data for tovecimig in biliary tract cancer and plans to meet with the FDA for a BLA discussion. The study met its primary ORR endpoint (17% vs 5%), while PFS and OS data are due late this quarter.

Seralutinib Shows Mixed Results in Phase 3 PAH Trial, Winrevair Benefits Heart Failure-Related PH

Apr 02, 2026

Phase 3 trial results show seralutinib missed its primary endpoint in PAH but showed benefit in advanced disease subgroups. Meanwhile, Winrevair demonstrated significant reductions in pulmonary vascular resistance in heart failure-related pulmonary hypertension in a Phase 2 study.